NEW YORK, Oct. 7, 2019 /PRNewswire-PRWeb/ -- GlycoMark, Inc. announces additional study data describing GlycoMark® test
The new study "GLYCOMARK 1,5-ANHYDROGLUCITOL AS A BIOMARKER OF SGLT2 INHIBITOR EFFECT" will be on display in the Madrid Marriott Auditorium Hotel and Conference Center on October 8 and attended by GlycoMark Clinical Affairs and study co-author, Jeff Dahlen, Ph.D. from 4 - 7 p.m. For interviews or to schedule a meeting with investigators or GlycoMark, please email GlycoMark@L3healthcare.com.
About the GlycoMark test The GlycoMark test quantitatively measures 1,5-anhydroglucitol (1,5-AG) from serum or plasma. The test is FDA cleared for professional use and indicated for the intermediate term monitoring of glycemic control in people with diabetes. The GlycoMark test has not been FDA cleared for monitoring SGLT-2 inhibitor effect.
About GlycoMark, Inc. GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East. The GlycoMark test is an FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at https://www.GlycoMark.com.
GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.
Subscribe to our Free Newsletters!